Lymphoma Treatment Prediction via Gene Expression Clustering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), lack specificity and effectiveness due to the clinical and biological heterogeneity of the disease, leading to variable patient responses to standard treatments like R-CHOP.
Innovation Solution
A method for predicting the responsiveness of lymphoma patients to cancer treatment by clustering reference lymphoma patients into subgroups based on gene expression levels and determining the subgroup of the patient, thereby predicting treatment responsiveness and potentially tailoring treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy treatments like R-CHOP are administered to all lymphoma patients, then treatment coverage is comprehensive, but treatment effectiveness varies due to disease heterogeneity
Solution Approach 1:
The patent segments lymphoma patients into distinct molecular subtypes (GCB-DLBCL, ABC-DLBCL, PMBL) based on gene expression profiling. This segmentation allows identification of specific patient groups with different treatment responses, enabling personalized treatment selection rather than uniform standard therapy for all patients.
Solution Approach 2:
The patent applies local quality by tailoring treatment approaches to specific molecular subtypes. Different chemotherapy regimens and targeted therapies are recommended for different subtypes (e.g., NF-κB pathway inhibitors for ABC-DLBCL), making the treatment quality specific to each patient's molecular characteristics rather than applying a one-size-fits-all approach.
2Adaptability or versatility
If gene expression profiling is performed to identify molecular subtypes, then treatment personalization is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent changes the diagnostic parameter from traditional clinical classification to molecular gene expression profiling. By measuring specific gene expression levels (e.g., BCL6, MUM1, CD10, BCL2) and comparing them against established thresholds, the system transforms complex biological data into discrete molecular subtype classifications that guide treatment decisions.
Solution Approach 2:
The patent introduces molecular subtyping as an intermediary between diagnosis and treatment selection. The gene expression profile serves as a mediator that translates complex disease heterogeneity into actionable treatment recommendations, bridging the gap between clinical presentation and personalized therapy selection.
Data Source
AI summary
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment comprising clustering patients into subgroups of patients using gene expression levels. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.